Recently, in accordance with the 'Administrative Measures for the Recognition of High-tech Enterprises' (Guo Ke Fa Huo [2016] No. 32) and the 'Guidelines for the Recognition of High-tech Enterprises' (Guo Ke Fa Huo [2016] No. 195), the Jiangsu Province recognition agency has announced the third batch of record filing lists for high-tech enterprises recognized in 2024. Following its designation as a 'High-tech Enterprise' in 2021. Laviana Pharma (Jiangsu) Co., Ltd. has successfully achieved high-tech enterprise recognition once again in Jiangsu Province.

Since its establishment, Laviana Pharma  has placed great importance on the accumulation and transformation of intellectual property, actively investing in research and development funds, and vigorously attracting high-end talent to continuously enhance the company's independent R&D capabilities. This recognition as a high-tech enterprise fully affirms the achievements of Laviana Pharma  in various aspects such as intellectual property, technology transfer, R&D organization management, and corporate growth.

Over the years, Laviana Pharma  (Jiangsu) Co., Ltd. has achieved significant progress in its corporate development. The company has successively obtained ISO9001. ISO45001. and ISO14001 certifications from TÜV Rheinland, was recognized as a high-tech enterprise in Jiangsu Province in 2009. designated as the Green Chemical Synthesis Research Center of Taizhou in 2010. recognized as an Enterprise Technology Center of Taizhou in 2020. and then identified as an Enterprise Technology Center of Jiangsu Province in 2024.

In terms of technological innovation achievements, five new invention patents and nine utility model patents will be granted in 2024. building a differentiated competitive advantage in key areas such as microreactor technology and enzyme-catalyzed synthesis. As one of the earliest companies in China to engage in CDMO services for small molecule innovative drugs, Laviana Pharma  has become a technology-driven innovative pharmaceutical R&D and manufacturing service (CDMO) enterprise with over 20 years of experience. Its services cover the entire chain from raw material drug process research and development to commercialization, including process research from preclinical to market, pilot production, commercial production services, and supporting approval assistance.

The approval of the recognition as a high-tech enterprise marks a new starting point for Laviana Pharma . In the future, the company will explore its lean development path by adhering to higher standards while staying in sync with policy guidance, maximizing its own value and systemic advantages. At the same time, the company will also play a leading and demonstrative role as a high-tech enterprise, further highlighting the vibrancy of innovation-driven development and contributing more strength to the country's high-tech innovation and development, continuing to write a more brilliant chapter in the wave of pharmaceutical innovation and R&D.